Table 4.

Univariable and Multivariable Analyses of Baseline Factors Associated With Symptomatic Nonresponse to TAVI

	Univariable		Multivariable
	OR (95% CI)	P Value	OR (95% CI)	P Value
NT‐proBNP >10 000 ng/L	113.33 (21.04–610.37)	<0.0001*	62.65 (6.47–664.99)	0.004 †
NT‐proBNP <800 ng/L	29.1 (6.73–54.59)	<0.0001*	40.68 (7.36–738.21)	0.0001 †
Estimated glomerular filtration rate (per 1 mL/min increase)	0.98 (0.97–1.01)	0.989	1.00 (0.96–1.04)	0.869
Chronic lung disease	2.78 (1.27–6.11)	0.010*	6.63 (0.83–53.34)	0.075
Atrial fibrillation	0.57 (0.24–1.35)	0.205	0.13 (0.01–3.09)	0.130
Left ventricular ejection fraction (per 1% increase)	0.98 (0.95–1.04)	0.298	0.99 (0.89–1.10)	0.991
Estimated left ventricular filling pressure	1.02 (0.97–1.16)	0.417	0.98 (0.97–1.10)	0.707
≥ Grade II diastolic dysfunction	1.79 (0.87–3.68)	0.109	1.18 (0.09–2.73)	0.138
≥ moderate mitral regurgitation	3.35 (1.18–9.44)	0.023*	4.30 (0.37–49.07)	0.240
≥ moderate tricuspid regurgitation	2.54 (0.96–6.76)	0.061	4.36 (1.06–11.80)	0.382
Pulmonary artery systolic pressure (per 1 mm Hg increase)	1.05 (1.02–1.10)	0.003*	1.05 (0.98–1.12)	0.205
Right ventricular dysfunction	3.86 (1.45–10.30)	0.007*	1.26 (0.15–10.86)	0.832

NT‐proBNP indicates N‐terminal pro‐brain natriuretic peptide; OR, odds ratio; and TAVI, transcatheter aortic valve implantation.

^*indicates significant univariable association.

^†significant multivariable association.